3/3
08:21 am
rntx
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Medium
Report
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
3/3
08:00 am
rntx
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
1/21
11:17 am
rntx
Rein Therapeutics (NASDAQ:RNTX) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
High
Report
Rein Therapeutics (NASDAQ:RNTX) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
1/21
10:12 am
rntx
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at Citigroup Inc. to a "hold" rating.
1/20
08:00 am
rntx
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
High
Report
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
12/14
01:26 am
rntx
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at
Wall Stree
Medium
Report
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at
Wall Stree